Masks of primary immunodeficiency disorders: diagnostic and therapeutic problems
https://doi.org/10.17650/2311-1267-2016-3-1-52-58
Abstract
Primary immunedifficiencies (PID) are genetically driven defects of immune system. Apart of relapsing severe infections, PIDs characterized by immune tolerance disturbance, chronic inflammation, autoimmunity and high risk of malignant diseases. Early diagnosing and in-time pathogenic therapy allows treatment of the majority of patients with PIDs and providing normal quality of life in other cases provides. Main pathogenic methods of treatment are hematopoietic stem cell transplantation and intravenous immunoglobulins (IVIGs) substitutional therapy. Usage of 10 % IVIGs allows decreasing time and economical costs of PIDs therapy.
About the Author
A. Yu. Shcherbina
Federal Research Center of Pediatric Hematology, Oncology and Immunology named after Dmitriy Rogachev, Ministry of Health of Russia; 1 Samory Mashela St., Moscow, 117997, Russia
Russian Federation
Russian Federation
References
1. Bousfiha A., Jeddane L., Al-Herz W. et al. The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies. J Clin Immunol 2015;35(8):727–38.
2. Иммунология детского возраста. Практическое руководство по детским болезням. Под ред. А.Ю. Щербины и Е.Д. Пашанова. М.: Медпрактика-М, 2006. [Childhood Immunology. A practical guide to children's illnesses. Ed.: A.Yu. Shcherbina, Ye.D. Pashanov. M.: Medpraktika-M, 2006. (In Russ.)].
3. Кондратенко И.В., Бологов А.А. Первичные иммунодефициты. М.: Медпрактика-М, 2005. [Kondratenko I.V., Bologov A.A. Primary immunodeficiencies. M.: Medpraktika-M, 2005. (In Russ.)].
4. Boyle J.M., Buckley R.H. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007;27(5):497–502.
5. Carneiro-Sampaio M., Moraes-Vasconcelos D., Kokron C.M. et al. Primary immunodeficiency diseases in different age groups: a report on 1,008 cases from a single Brazilian reference center. J Clin Immunol 2013;33(4):716–24.
6. Lucas C.L., Kuehn H.S., Zhao F. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat Immunol 2014;15(1):88–97.
7. Lucas C.L., Zhang Y., Venida A. et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J Exp Med 2014;211(13):2537–47.
8. Joshi A.Y., Iyer V.N., Hagan J.B. et al. Incidence and temporal trends of primary immunodeficiency: a population-based cohort study. Mayo Clin Proc 2009;84(1):16–22.
9. Conley M.E., Notarangelo L.D., Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999;93:190–7.
10. Canioni D., Jabado N., MacIntyre E. et al. Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. Histopathology 2001;38:146–59.
11. Folds J.D., Schmitz J.L. Clinical and laboratory assessment of immunity. J Allergy Clin Immunol 2004;111(Suppl. 2):S702–11.
12. Balashov D., Shcherbina A., Maschan M. et al. Single-Center Experience of Unrelated and Haploidentical Stem Cell Transplantation with TCRαβ and CD19 Depletion in Children with Primary Immunodeficiency Syndromes. Biol Blood Marrow Transplant 2015;21(11):1955–62.
13. Fischer A., Hacein-Bey Abina S., Touzot F., Cavazzana M. Gene therapy for primary immunodeficiencies. Clin Genet 2015;88(6):507–15.
14. Orange J.S., Grossman W.J., Navickis R.J., Wilkes M.M. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol 2010;137(1):21–30.
15. Щербина А.Ю., Косачева Т.Г., Румянцев А.Г. Первичные иммунодефицитные состояния: вопросы диагностики и лечения. Вопросы гематологии/онкологии и иммунопатологии в педиатрии 2010;9(2):23–31. [Shcherbina A.Yu., Kosacheva T.G., Rumyantsev A.G. Primary immunodeficiency: diagnostic issues and treatment. Voprosy gematologii/onkologii i immunopatologii v pediatrii = Pediatric Hematology/Oncology and Immunopathology 2010;9(2):23–31. (In Russ.)].
16. Kumar А., Teuber S.S., Gershwin M.E. Intravenous immunoglobulin: striving for appropriate use. Int Arch Allergy Immunol 2006;140(3):185–98.
17. Chérin P., Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. Bio Drugs 2010;24(4):211–23.
18. Смирнова И.Н., Косачева Т.Г., Швец О.В. и др. Использование препарата 10 % иммуноглобулина для внутривенного введения Гамуекс в лечении больных с первичными иммунодефицитами: собственный опыт и обзор литературы. Российский аллергологический журнал 2014;6:76–81. [Smirnova I.N., Kosacheva T.G., Shvets O.V. et al. 10 % intravenous immunoglobulin Gamunex in the treatment of primary immunodeficiencies patients: own experience and literature review. Rossiyskiy allergologicheskiy zhurnal = Russian Allergology Journal 2014;6:76–81. (In Russ.)].
19. Lozano-Blasco J., Martín-Mateos M.A., Alsina L. et al. A 10 % liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG. Allergol Immunopathol (Madr) 2014;42(2):136–41.
20. Champi C. Primary immunodeficiency disorders in children: prompt diagnosis can lead to lifesaving treatment. J Pediatr Health Care 2002;16(1):16–21.
Review
For citations:
Shcherbina A.Yu. Masks of primary immunodeficiency disorders: diagnostic and therapeutic problems. Russian Journal of Pediatric Hematology and Oncology. 2016;3(1):52-58. (In Russ.) https://doi.org/10.17650/2311-1267-2016-3-1-52-58
Views:
2241
Email this article 